{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:21:46Z","timestamp":1789154506759,"version":"build-2803163510"},"reference-count":7,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:p>Intestinal sarcomas are rare gastrointestinal tumors but their etiology is not clear. A middle-aged man was admitted to hospital on 11 April 2023 because of intermittent melena for 1\u2005month. Gastroscopy and colonoscopy were inconclusive, however, melena persisted. Abdominal magnetic resonance imaging indicated a left mid-abdominal mass and lymphoma of the small bowel origin. Small bowel enteroscopy revealed infiltrating periannular ulcer lesions in the jejunum. He underwent an operation and a partial resection of the small intestine was performed. The pathological examination revealed mesenchymal, highly malignant, poorly differentiated sarcoma. The patient died 6\u2005months after surgery. The patient had been diagnosed with hepatocellular cancer and received immune checkpoint inhibitors (PD-1, sintilimab) combined with bevacizumab for 14 cycles 19\u2005months before being diagnosed with intestinal sarcoma, and achieved complete remission. While immunotherapy achieves good therapeutic effects, another problem that has to be paid attention to is immune-related adverse reactions, which involve multiple systems. Based on the above information, we believe that this small bowel sarcoma was a rare complication of immunotherapy.<\/jats:p>","DOI":"10.3389\/fsurg.2025.1456485","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T07:07:24Z","timestamp":1741676844000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A rare small bowel sarcoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Jiwu","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101860","DOI":"10.1016\/j.bpg.2023.101860","article-title":"Updates in the diagnosis and management of small-bowel tumors","author":"Vlachou","year":"2023","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.14348\/molcells.2023.0079","article-title":"Sarcoma immunotherapy: confronting present hurdles and unveiling upcoming opportunities","volume":"46","author":"Jeong","year":"2023","journal-title":"Mol Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.3390\/curroncol30060439","article-title":"Current landscape of immune checkpoint inhibitor therapy for hepatocellular carcinoma","volume":"30","author":"Ruff","year":"2023","journal-title":"Curr Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1080\/1744666X.2023.2221434","article-title":"Updates in toxicities associated with immune checkpoint inhibitors","volume":"19","author":"Curkovic","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.17998\/jlc.2023.11.21","article-title":"Complications of immunotherapy in advanced hepatocellular carcinoma","volume":"24","author":"Song","year":"2024","journal-title":"J Liver Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"216661","DOI":"10.1016\/j.canlet.2024.216661","article-title":"Immune checkpoints between epithelial-mesenchymal transition and autophagy: a conflicting triangle","volume":"585","author":"Cordani","year":"2024","journal-title":"Cancer Lett"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2025.1456485\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T07:07:26Z","timestamp":1741676846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2025.1456485\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":7,"alternative-id":["10.3389\/fsurg.2025.1456485"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2025.1456485","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"article-number":"1456485"}}